Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Hospital, Bordeaux
With
Merck Serono International SA
ADERA
30 patients distributed in 3 groups of 10 patients with specific inclusion criteria will participate in this trial:
* 10 MS patients in early disease onset,
* 10 MS patients under Natalizumab treatment
* and control group of 10 patients with other neurological diseases.
The aim of this clinical trial is to detect the CD8+ myelin specific T-Cells in the blood of Multiple Sclerosis patients.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Group 1: HLA-A2 patients whose Multiple Sclerosis has just been diagnosed
18 year old and older patients,
HLA-A2 Patients with Multiple Sclerosis or clinically isolated syndrome at high risk of being affected by Multiple Sclerosis (criteria of spatial scattering according to the 2010 or 2005 McDonald's criteria)
Patients without treatment or treated with immunomodulating therapy
Patients affiliated to health insurance coverage
Information and comprehensive agreement signed by the patient and the investigator
Group 2: HLA-A2 patients hospitalized in the neurology department who are not affected with a neuroimmunological disorder
18 year old and older patients,
HLA-A2 patients hospitalized in the neurology department
Patient not affected by Multiple Sclerosis or a related inflammatory disorder
Affiliated or profitable subject of a national insurance scheme
Patients affiliated to health insurance coverage
Information and comprehensive agreement signed by the patient and the investigator
Group 3: HLA-A2 Multiple Sclerosis patients treated by Natalizumab therapy
18 year old and older patients,
HLA-A2 patients with relapsing remitting (RR) MS fulfilling McDonald 2005 or 2010 Multiple Sclerosis diagnostic criteria
Patients treated by Natalizumab therapy for at least 3 months
Patients affiliated to health insurance coverage
Information and comprehensive agreement signed by the patient and the investigator
You may not be if
Group 1 and 3:
Patients undergoing immunosuppressive therapy at present or in the past except Natalizumab
Pregnant women
Group 2:
Patients undergoing immunosuppressive therapy at present or in the past
Patients affected by Multiple Sclerosis or a related disorder
Pregnant women
Clareo Health | Preliminary Study for Selective Detection of the CD8+ Myelin Specific T Cell in the Blood of Multiple Sclerosis Patients
